Demeterherb pitches route-based CoQ10 buying model

Xi'an Demeter Biotech is framing coenzyme Q10 procurement around production route, assay and finished-product documentation rather than marketing labels. The company says buyers need comparable data on fermentation and synthesis grades to choose the right material for formulation and release.

Why it matters: - Coenzyme Q10 buyers need more than a purity claim to qualify material for softgels, capsules, tablets or functional foods. - Route disclosure, assay data, isomer profile, carrier system and batch test results all affect product fit, regulatory review and supply consistency. - Demeterherb is positioning its one-stop model as a way to keep those technical and commercial decisions tied to one record.

What happened: - Xi'an Demeter Biotech Co., Ltd. outlined a procurement framework for CoQ10 that separates production route from finished-product specification. - The company says buyers should know whether a grade comes from microbial fermentation or chemical synthesis, then confirm identity, assay, analytical method, carrier and batch consistency. - Demeterherb says its CoQ10 lineup includes powder at 10%-98%, water-soluble CoQ10 powder at 10%-20%, and Liposomal CoQ10 at 50% or 70%. - The company says those products come with HPLC testing, sample and COA support, and a 24-month shelf life.

The details: - Microbial fermentation produces CoQ10 through a biological system, while chemical synthesis builds the molecule through controlled reactions and purification steps. - Published biotechnology reviews cited in the release point to stereoselectivity and isomer separation as key issues in chemical synthesis. - The release says microbial production is valued for yielding optically defined material through a biological route. - A 98% CoQ10 statement describes assay concentration, not production route. - A fermentation-derived claim does not prove 98% purity, all-trans profile or a specific impurity limit. - Demeterherb says its products are built for different formulation needs: concentrated powder for conventional dosage forms, water-soluble systems for aqueous applications, and liposomal systems for improved dispersibility. - The company says its one-stop services include private label hard capsules, soft capsules, tablets, granules and customized packaging. - Demeterherb says its logistics options include express, air, sea, railway and truck shipping. - The company says its ingredient buyers are in more than 50 countries and regions.

Between the lines: - The release argues that “natural,” “fermented,” “synthetic” and “high purity” are not enough on their own to approve a CoQ10 ingredient. - The practical standard, as framed by Demeterherb, is information completeness and batch reproducibility. - The company is also signaling that procurement, quality, formulation and regulatory teams should each review different parts of the file before approval. - That approach reduces the risk that a marketing label replaces the technical record a buyer needs.

What's next: - Buyers can request the current specification, route information for the selected grade, sample, COA, packaging plan and quotation from Demeterherb. - Demeterherb says the final approval record should define ownership across procurement, quality, formulation and regulatory teams. - The company says route disclosure and lot-level analytical evidence, not organic certification, control release for its CoQ10 grades.

The bottom line: - Demeterherb’s pitch is simple: compare CoQ10 on route disclosure plus finished-product evidence, not on labels alone.